A novel metabolic-immune related signature predicts prognosis and immunotherapy response in lung adenocarcinoma

BACKGROUND: Lung adenocarcinoma (LUAD) is one of the most frequent types of lung cancer, with a high mortality and recurrence rate. This study aimed to design a RiskScore to predict the prognosis and immunotherapy response of LUAD patients due to a lack of metabolic and immune-related prognostic mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xiaolong, Qi, Chumei, Zhou, Honghong, Liu, Yongshuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396642/
https://www.ncbi.nlm.nih.gov/pubmed/36016532
http://dx.doi.org/10.1016/j.heliyon.2022.e10164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396642/
https://www.ncbi.nlm.nih.gov/pubmed/36016532
http://dx.doi.org/10.1016/j.heliyon.2022.e10164

Ejemplares similares